Why Amarin Stock Is Getting Slammed Today
Shares of the mid-cap biopharma Amarin (NASDAQ: AMRN) plummeted by as much as 31% Wednesday on over 10 times the normal daily volume. The drugmaker's shares were tanking today in response to an appeals hearing over the patents for its heart medication Vascepa.
Amarin's shares bounced off their lows of the day, but then closed today down almost 31%.
Image source: Getty Images.
Source Fool.com
